Introduction: Palliative radical cystectomy (pRC) may be offered to selected bladder cancer (BC) patients with grievous local symptoms. However, there is only scarce information on perioperative complications and prognosis, especially in the case of metastatic spread. We intended to analyze morbidity and oncological outcome in this patient subgroup. Materials: Patients undergoing pRC because of BC with radiologic evidence of metastases were included in this retrospective study. Perioperative adverse events (AEs) were graded by the Clavien-Dindo Classification system. All patients underwent CT-based surveillance, and questionnaires were sent for survival follow-up in predefined intervals. Oncological outcome and predictive markers were assessed in univariate and multivariate analyses, using log-rank tests and Cox-regression analyses. Results: Between 2004 and 2016, 77 patients were identified. Median age at surgery was 70 years (IQR 66–77) and the median follow-up time was 12 months (IQR 4–44). Preoperative staging revealed pulmonary, hepatic, bone, peritoneal, and various other metastasis in 46/77 (60%), 14/77 (18%), 11/77 (14%), 5/77 (7%), and 11/77 (14%) cases, respectively. Most frequently observed symptoms at the time of pRC were severe gross hematuria (n = 41) and intense pain (n = 11). Most AEs were of minor grade (83%). The median length of stay was 20 days. Median CSS was 13 months with a 5-year CSS of 34%. Intriguingly and unsuspectedly, preoperatively suspicious lung lesions were confirmed during surveillance only in 33%, respectively. In multivariate analysis, intraoperative blood transfusions (HR = 2.25, 95% CI: 1.09–4.63, p = 0.028) were significantly associated with decreased CSS. The best outcome was observed in patients with only subpleural metastases (CSS 80 months, p = 0.039) and normal CRP- and Hb values. Conclusion: pRC can be performed with acceptable perioperative morbidity and mortality. Pulmonary lesions seem to have a risk of false-positive results and should be biopsied in all uncertain cases. Localization of lung metastases together with preoperative CRP- and Hb levels seem to play a prognostic role.

1.
Ferlay
J
,
Steliarova-Foucher
E
,
Lortet-Tieulent
J
,
Rosso
S
,
Coebergh
JW
,
Comber
H
,
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012
.
Eur J Cancer
.
2013
;
49
(
6
):
1374
403
.
2.
Gust
KM
,
Rebhan
K
,
Resch
I
,
Shariat
SF
,
Necchi
A
.
Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer
.
Curr Opin Urol
.
2020
;
30
(
4
):
547
56
. .
3.
Raman
SP
,
Fishman
EK
.
Upper and lower tract urothelial imaging using computed tomography urography
.
Urol Clin North Am
.
2018
;
45
(
3
):
389
405
. .
4.
Hautmann
RE
,
Gschwend
JE
,
de Petriconi
RC
,
Kron
M
,
Volkmer
BG
.
Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era
.
J Urol
.
2006
;
176
(
2
):
486
2
; discussion 491–2. .
5.
Pfister
D
,
Porres
D
,
Epplen
R
,
von Erps
T
,
Heidenreich
A
.
[Palliative radical (cysto)prostatectomy in locally advanced castration-resistant prostate cancer]
.
Urologe A
.
2011
;
50
(
9
):
1101
5
. German. .
6.
Nagele
U
,
Anastasiadis
AG
,
Merseburger
AS
,
Hennenlotter
J
,
Horstmann
M
,
Sievert
KD
,
Surgical approach in patients with T4 bladder cancer as primary treatment: disaster or option with improved quality of life
.
Indian J Urol
.
2008
;
24
(
1
):
95
8
.
7.
Madersbacher
S
,
Hochreiter
W
,
Burkhard
F
,
Thalmann
GN
,
Danuser
H
,
Markwalder
R
,
Radical cystectomy for bladder cancer today: a homogeneous series without neoadjuvant therapy
.
J Clin Oncol
.
2003
;
21
(
4
):
690
6
.
8.
Kretschmer
A
,
Grimm
T
,
Buchner
A
,
Grabbert
M
,
Jokisch
F
,
Schneevoigt
BS
,
Prospective evaluation of health-related quality of life after radical cystectomy: focus on peri- and postoperative complications
.
World J Urol
.
2017
;
35
(
8
):
1223
31
.
9.
Kretschmer
A
,
Grimm
T
,
Buchner
A
,
Stief
CG
,
Karl
A
.
Prognostic features for quality of life after radical cystectomy and orthotopic neobladder
.
Int Braz J Urol
.
2016
;
42
(
6
):
1109
20
. .
10.
Karl
A
,
Buchner
A
,
Becker
A
,
Staehler
M
,
Seitz
M
,
Khoder
W
,
A new concept for early recovery after surgery for patients undergoing radical cystectomy for bladder cancer: results of a prospective randomized study
.
J Urol
.
2014
;
191
(
2
):
335
40
.
11.
Stein
JP
,
Lieskovsky
G
,
Cote
R
,
Groshen
S
,
Feng
AC
,
Boyd
S
,
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients
.
J Clin Oncol
.
2001
;
19
(
3
):
666
75
.
12.
Herr
HW
,
Donat
SM
.
Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy
.
J Urol
.
2001
;
165
(
1
):
62
4
; discussion 64. .
13.
Metcalfe
MJ
,
Smaldone
MC
,
Lin
DW
,
Aparicio
AM
,
Chapin
BF
.
Role of radical prostatectomy in metastatic prostate cancer: a review
.
Urol Oncol
.
2017
;
35
(
4
):
125
34
.
14.
Heidenreich
A
,
Pfister
D
,
Porres
D
.
Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study
.
J Urol
.
2015
;
193
(
3
):
832
8
. .
15.
Liu
W
,
Laitinen
S
,
Khan
S
,
Vihinen
M
,
Kowalski
J
,
Yu
G
,
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer
.
Nat Med
.
2009
;
15
(
5
):
559
65
.
16.
Khokhar
S
,
Vickers
A
,
Moore
MS
,
Mironov
S
,
Stover
DE
,
Feinstein
MB
.
Significance of non-calcified pulmonary nodules in patients with extrapulmonary cancers
.
Thorax
.
2006
;
61
(
4
):
331
6
. .
17.
Heaton
TE
,
Hammond
WJ
,
Farber
BA
,
Pallos
V
,
Meyers
PA
,
Chou
AJ
,
A 20-year retrospective analysis of CT-based pre-operative identification of pulmonary metastases in patients with osteosarcoma: a single-center review
.
J Pediatr Surg
.
2017
;
52
(
1
):
115
9
.
18.
Ciccarese
F
,
Bazzocchi
A
,
Ciminari
R
,
Righi
A
,
Rocca
M
,
Rimondi
E
,
The many faces of pulmonary metastases of osteosarcoma: retrospective study on 283 lesions submitted to surgery
.
Eur J Radiol
.
2015
;
84
(
12
):
2679
85
.
19.
Paik
ML
,
Scolieri
MJ
,
Brown
SL
,
Spirnak
JP
,
Resnick
MI
.
Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy
.
J Urol
.
2000
;
163
(
6
):
1693
6
. .
20.
Cahn
D
,
McGreen
B
,
Lee
A
,
Ruth
K
,
Plimack
E
,
Geynisman
D
,
MP58-12: clinical destiny of indeterminate pulmonary nodules in patients unergoing radical cystectomy for urothelial carcinoma of the bladder
.
J Urol
.
2017
;
197
(
4S
):
e776
7
.
21.
Heidenreich
A
,
Albers
P
,
Classen
J
,
Graefen
M
,
Gschwend
J
,
Kotzerke
J
,
Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society
.
Urol Int
.
2010
;
85
(
1
):
1
10
.
22.
von der Maase
H
,
Sengelov
L
,
Roberts
JT
,
Ricci
S
,
Dogliotti
L
,
Oliver
T
,
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
.
J Clin Oncol
.
2005
;
23
(
21
):
4602
8
.
23.
Rodler
S
,
Buchner
A
,
Ledderose
ST
,
Eismann
L
,
Volz
Y
,
Pfitzinger
P
,
Prognostic value of pretreatment inflammatory markers in variant histologies of the bladder: is inflammation linked to survival after radical cystectomy?
World J Urol
.
2021
;
39
(
7
):
2537
43
.
24.
Schulz
GB
,
Grimm
T
,
Buchner
A
,
Jokisch
F
,
Grabbert
M
,
Schneevoigt
BS
,
Prognostic value of the preoperative platelet-to-leukocyte ratio for oncologic outcomes in patients undergoing radical cystectomy for bladder cancer
.
Clin Genitourin Cancer
.
2017
;
15
(
6
):
e915
21
.
25.
Buchner
A
,
Grimm
T
,
Schneevoigt
BS
,
Wittmann
G
,
Kretschmer
A
,
Jokisch
F
,
Dramatic impact of blood transfusion on cancer-specific survival after radical cystectomy irrespective of tumor stage
.
Scand J Urol
.
2017
;
51
(
2
):
130
6
.
26.
Volz
Y
,
Eismann
L
,
Pfitzinger
PL
,
Jokisch
JF
,
Buchner
A
,
Schlenker
B
,
Prognostic impact of perioperative blood transfusions on oncological outcomes of patients with bladder cancer undergoing radical cystectomy: a systematic review
.
Arab J Urol
.
2020
;
19
(
1
):
24
30
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.